USANA Health Sciences, Inc. (NYSE:USNA) CEO Jim Brown Sells 5,000 Shares

USANA Health Sciences, Inc. (NYSE:USNA) CEO Jim Brown sold 5,000 shares of USANA Health Sciences stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $29.47, for a total value of $147,350.00. Following the transaction, the chief executive officer now directly owns 15,716 shares in the company, valued at approximately $463,150.52. This trade represents a 24.14 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

USANA Health Sciences Stock Performance

Shares of NYSE USNA opened at $29.72 on Wednesday. The stock has a market cap of $566.44 million, a price-to-earnings ratio of 10.50, a PEG ratio of 0.93 and a beta of 0.87. The business has a 50 day simple moving average of $33.34 and a 200 day simple moving average of $36.41. USANA Health Sciences, Inc. has a 52 week low of $27.71 and a 52 week high of $50.32.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.49 by $0.15. The business had revenue of $213.61 million during the quarter, compared to analysts’ expectations of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. On average, analysts predict that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Sidoti cut USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. Finally, DA Davidson lowered their target price on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday, February 27th.

Institutional Investors Weigh In On USANA Health Sciences

Several large investors have recently made changes to their positions in the company. Martingale Asset Management L P boosted its position in USANA Health Sciences by 2.1% during the third quarter. Martingale Asset Management L P now owns 16,732 shares of the company’s stock worth $634,000 after purchasing an additional 340 shares during the period. KBC Group NV boosted its position in USANA Health Sciences by 96.6% during the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock worth $40,000 after purchasing an additional 519 shares during the period. R Squared Ltd bought a new stake in USANA Health Sciences during the fourth quarter worth approximately $28,000. Safe Harbor Fiduciary LLC bought a new stake in USANA Health Sciences during the third quarter worth approximately $30,000. Finally, Exchange Traded Concepts LLC boosted its position in USANA Health Sciences by 11.3% during the fourth quarter. Exchange Traded Concepts LLC now owns 8,578 shares of the company’s stock worth $308,000 after purchasing an additional 869 shares during the period. Institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.